Bactevo Ltd. has entered into a drug discovery collaboration agreement with Boehringer Ingelheim to identify novel small molecule lead compounds. This collaboration leverages Bactevo’s revolutionary TIME (Totally Integrated Medicines Engine) platform, incorporating its ground-breaking synthetic chemistry technology, designed specifically to combine medicinally-relevant ‘tagless’ chemical diversity with ultra-fast phenotypic or molecular target screening in human samples, to further enhance speed, efficiency and quality in identifying novel in vivo enabled leads for undisclosed Boehringer Ingelheim programs of interest.
Under the terms of this multi-program agreement, Bactevo will receive upfront payments and research funding, and be eligible for additional research, development and commercialization milestone payments.
(Source: Bactevo Ltd.)
